Fulcrum: Strong EPS Growth Despite Sales Disappointment

  Fulcrum Therapeutics exceeded expectations by reporting a loss of $(0.38) per share, surpassing the analyst consensus estimate of $(0.44) by an impressive 13.64%.

Sales: Unfortunately, the company fell short of projections with quarterly sales amounting to $880.00 thousand, missing the analyst consensus estimate of $1.60 million by a significant 45.00%.

Year-over-Year Comparison: Despite the sales disappointment, Fulcrum Therapeutics showcased promising growth in terms of EPS. The reported loss of $(0.38) per share signifies a remarkable 54.22% increase compared to the $(0.83) loss per share recorded during the same period last year. However, it’s worth noting that the sales figures of $880.00 thousand experienced a considerable 53.24% decline in comparison to the $1.88 million sales from the previous year.

https://beststocks.com/fulcrum-therapeutics-reports-strong-eps-growt/